Aurobindo Pharma Ltd rises for third straight session

Aurobindo Pharma Ltd is quoting at Rs 1197.8, up 1.65% on the day as on 12:49 IST on the NSE. The stock is up 5.66% in last one year as compared to a 9.94% jump in NIFTY and a 26.31% jump in the Nifty Pharma index.

Aurobindo Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1197.8, up 1.65% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.64% on the day, quoting at 23350.8. The Sensex is at 77182.56, up 0.74%. Aurobindo Pharma Ltd has slipped around 4.4% in last one month.

Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has slipped around 1.96% in last one month and is currently quoting at 22061.7, up 0.31% on the day. The volume in the stock stood at 4.31 lakh shares today, compared to the daily average of 11.52 lakh shares in last one month.

The benchmark January futures contract for the stock is quoting at Rs 1197.6, up 1.54% on the day. Aurobindo Pharma Ltd is up 5.66% in last one year as compared to a 9.94% jump in NIFTY and a 26.31% jump in the Nifty Pharma index.

  • Related Posts

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    New Delhi: The Parliamentary Panel on Health and Family Welfare has recommended various significant regulatory changes in the regulation of medical devices, including decentralisation of approval for all medical devices…

    Diabetic drug metformin found to act on brain

    NEW DELHI:  Cheap, effective and widely trusted, metformin has long been the first choice for treating type 2 diabetes. Now, scientists say the drug works in a way few had…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory